Klinik Araştırma

Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis

Cilt: 36 Sayı: 2026 22 Nisan 2026
PDF İndir
TR EN

Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis

Öz

Aim: This study evaluated the relationship between two‑year changes in hematological and inflammatory parameters—including red cell distribution width–standard deviation (RDW‑SD)—and disease progression and treatment response in relapsing‑remitting multiple sclerosis (RRMS) patients receiving dimethyl fumarate (DMF).
Materials and Methods:  This retrospective study included 58 RRMS patients receiving uninterrupted DMF treatment. Hematological data from two years prior and current values were compared. Parameters analyzed included white blood cell count (WBC), lymphocytes, monocytes, RDW‑SD, and inflammatory indices such as neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR). Normality was assessed by the Kolmogorov–Smirnov test, and paired t‑test, Wilcoxon signed-rank test , and Spearman correlation analyses were applied as appropriate.
Results: Significant increases in RDW-SD (p<0.001), NLR (p=0.005), MLR (p=0.003), and PLR (p=0.001) were observed after DMF treatment. Lymphocyte counts decreased significantly (p=0.002). Statistically significant correlations were observed between the change in monocyte count and the Expanded Disability Status Scale (EDSS) score (r=0.386; p=0.003), and between the change in platelet‑to‑monocyte ratio (PMR) and EDSS (r=–0.297; p=0.023). Notably, the increase in RDW‑SD was independent of the conventional RDW-coefficient of variation (CV) (p=0.57).
Conclusions: The increase in RDW-SD levels observed during DMF treatment suggests that this parameter may be associated with inflammatory activity. RDW-SD could be evaluated as an auxiliary biomarker in personalized treatment approaches. However, further research is needed to confirm these findings.

Anahtar Kelimeler

Dimethyl fumarate, Multiple sclerosis, Red cell distribution width, Inflammation mediators, Immunomodulation

Destekleyen Kurum

None

Proje Numarası

Not Applicable

Etik Beyan

Ethical approval: This retrospective study was approved by the Aksaray University Health Sciences Scientific Research Ethics Committee (Decision No: 2025/86, Meeting Date: 15.05.2025, Protocol: SAGETİK 2025-61). All procedures were conducted in accordance with the principles of the Declaration of Helsinki.

Kaynakça

  1. 1. Woo MS, Engler JB, Friese MA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci. 2024;25(7):493–513.
  2. 2. Stadelmann C, Franz J, Nessler S. Recent developments in multiple sclerosis neuropathology. Curr Opin Neurol. 2025;38(10):1097–1103.
  3. 3. Pandey KS, Giles K, Balashov K, Macdonell R, Windsheimer J, Martinez M, et al. Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: Final analysis of the ESTEEM study. Neurol Ther. 2025;14(1):243–260.
  4. 4. Blair HA. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2019;79(18):1965–1976.
  5. 5. Hosseini A, Masjedi A, Baradaran B, Hojjat-Farsangi M, Ghalamfarsa G, Anvari E, et al. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. J Cell Physiol. 2019;234(7):9943–9955.
  6. 6. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107.
  7. 7. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
  8. 8. Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Mokliatchouk O, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022;28(5):801–816.
  9. 9. Constantino BT. Red cell distribution width, revisited. Lab Med. 2013;44(2):e2–e9.
  10. 10. Ünlü MD, Demirci S. Sensitivity of platelet-lymphocyte ratio, monocyte-lymphocyte ratio, neutrophil-lymphocyte ratio, red blood cell distribution width and systemic immune inflammatory index in multiple sclerosis patients: relationship with disease subtypes and disability. Kocatepe Tip Derg. 2024;25(3):315–321.

Kaynak Göster

APA
Sahin, O., & Güneş, M. (2026). Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis. Genel Tıp Dergisi, 36(2026), 1-6. https://doi.org/10.54005/geneltip.1750288
AMA
1.Sahin O, Güneş M. Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis. Genel Tıp Derg. 2026;36(2026):1-6. doi:10.54005/geneltip.1750288
Chicago
Sahin, Oruc, ve Muzaffer Güneş. 2026. “Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis”. Genel Tıp Dergisi 36 (2026): 1-6. https://doi.org/10.54005/geneltip.1750288.
EndNote
Sahin O, Güneş M (01 Nisan 2026) Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis. Genel Tıp Dergisi 36 2026 1–6.
IEEE
[1]O. Sahin ve M. Güneş, “Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis”, Genel Tıp Derg, c. 36, sy 2026, ss. 1–6, Nis. 2026, doi: 10.54005/geneltip.1750288.
ISNAD
Sahin, Oruc - Güneş, Muzaffer. “Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis”. Genel Tıp Dergisi 36/2026 (01 Nisan 2026): 1-6. https://doi.org/10.54005/geneltip.1750288.
JAMA
1.Sahin O, Güneş M. Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis. Genel Tıp Derg. 2026;36:1–6.
MLA
Sahin, Oruc, ve Muzaffer Güneş. “Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis”. Genel Tıp Dergisi, c. 36, sy 2026, Nisan 2026, ss. 1-6, doi:10.54005/geneltip.1750288.
Vancouver
1.Oruc Sahin, Muzaffer Güneş. Two-year Red Cell Distribution Width–Standard Deviation Change in Multiple Sclerosis Patients Receiving Dimethyl Fumarate Treatment: A Retrospective Analysis. Genel Tıp Derg. 01 Nisan 2026;36(2026):1-6. doi:10.54005/geneltip.1750288